Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
    • Transcripts
    • AGM Invitations
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

ExpreS2ion Biotechnologies - Presentation of Q1 2025

By HC Andersen Capital
ExpreS2ion Biotech Holding

You can already now sign up for the event and send in your questions. You don’t have to participate live to submit your questions for the event.

ExpreS2ion Biotechnologies is expected to release its Q1 2025 results on 15 May 2025. Later on the same day at 10:30, the management will present the results and the achievements in an online live presentation. The presentation will be followed by a Q&A session.

Besides the financial results for the first quarter, focus could be on the capital situation and runway through 2025, as well as update on the timelines and development in the pipeline, especially seen in the light of the update the company released late March regarding the phase 1 trial for ExpreS2ion’s HER2 cancer vaccine candidate, ES2B-C001. Despite expectations of dosing the first patient during Q1 2025, no patients have been dosed yet, but with the company stating that the delay has nothing to do with any safety or scientific concerns. Furthermore, on the back of a strategic review, ExpreS2ion also decided not to pursue further development of its CMV vaccine candidate, a development conducted in collaboration with Evaxion Biotech.

ExpreS2ion Biotechnologies is a Danish pharmaceutical company, which focuses on the development of vaccines through the use of its ExpreS2 production platform with AdaptVac's VLP technology.

Disclaimer: HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Digital IR/Corporate Visibility subscription agreement. /Michael Friis, 11.57 9 April 2025.

Recent videos

Gubra – Presentation of Phase 1 Topline Results on ABBV-295 long-acting amylin analog
10.03.2026 klo 14.30 Gubra
Hanza, Capital Markets Day, CMD, 2026
10.03.2026 klo 14.00 HANZA
Scanfil Q4’25: Horizontal operational progress
09.03.2026 klo 11.26 Scanfil
Aiforia, Webcast, H2, 2025
06.03.2026 klo 10.00 Aiforia Technologies
Nightingale, Webcast, Half-year financial report 1 July–31 December 2025
05.03.2026 klo 14.00 Nightingale Health
View all videos
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.